AI: DeepSeek (deepseek-chat)

Q: {
  "prompt": "Please analyze the clinical note against the provided guideline and suggest improvements to better align with the guideline recommendations.\n\nFor each recommendation, specify:\n1. The type of recommendation:\n   - Additional information needed (history/examination/investigations)\n   - Improved patient advice (options/statistics/patient information)\n   - Different management plan\n2. The specific recommendation\n3. The reason for the recommendation (referencing the guideline)\n\nCategorize each recommendation by importance:\n- Very Important: Critical for patient safety or guideline compliance\n- Somewhat Important: Significant for optimal care but not critical\n- Less Important: Would improve care but not essential\n- Unimportant: Minor suggestions that could be considered\n\nFormat the response as follows:\n\n### Very Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Somewhat Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Less Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Unimportant Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\nClinical Note:\nSITUATION: 29-year-old G2P1 at 11+3 weeks gestation presenting with vaginal bleeding and cramping consistent with inevitable miscarriage\n\nBACKGROUND: Mrs Peterson has experienced light vaginal bleeding for the past 3 days, initially spotting that she hoped was implantation bleeding. However, bleeding has increased to moderate flow with dark red blood and small clots. She developed cramping lower abdominal pain yesterday, described as severe period-like pain occurring in waves every 10-15 minutes. She passed some tissue this morning which she brought in a container. No fever, no offensive discharge, no urinary symptoms. This pregnancy was planned and much wanted after 8 months of trying. Her first pregnancy 4 years ago was uncomplicated with normal vaginal delivery at term. Last menstrual period was 12 weeks ago, pregnancy confirmed by home test and GP at 6+ weeks. Dating scan was booked for next week. She has been feeling less nauseous over the past week, which concerned her. No significant medical history, taking folic acid and pregnancy vitamins.\n\nASSESSMENT: Patient appears upset but hemodynamically stable. Vital signs: BP 118/76 mmHg, HR 88 bpm, temp 36.8Â°C. Abdominal examination reveals mild suprapubic tenderness, no guarding, no masses palpable. Speculum examination shows moderate dark red bleeding from cervical os with tissue visible in posterior fornix. Cervical os appears open approximately 1cm. Bimanual examination confirms open cervix, uterus smaller than expected for dates (approximately 8-week size), no adnexal masses or tenderness. Pregnancy test (urine) still positive but weaker than previous tests. Transvaginal ultrasound shows irregular gestational sac measuring 6+2 weeks equivalent, no fetal pole visible, no fetal heart activity detected. Some retained products of conception visible.\n\nRECOMMENDATION: Diagnosis of inevitable miscarriage with incomplete evacuation. Options discussed including expectant management, medical management (misoprostol), or surgical management (ERPC). Given patient preference and retained products visible on scan, surgical management recommended. ERPC scheduled for tomorrow morning after overnight fasting. Pre-operative bloods including FBC, cross-match. Rhesus status checked - patient is Rhesus negative so anti-D immunoglobulin required. Antibiotics (doxycycline) prescribed prophylactically. Pain relief with codeine and ibuprofen. Emotional support provided, bereavement counseling referral offered. Follow-up in 2 weeks to ensure complete evacuation and provide ongoing support. Advised to avoid intercourse and tampons for 2 weeks post-procedure.\n\nGuideline:\n[ID] nice-guidance-2023-ectopic-pdf\nTitle: NICE Guidance - 2023 - Ectopic.pdf\nContent: Ectopic pregnancy and miscarriage: diagnosis and initial management guideline covers diagnosing and managing ectopic pregnancy and miscarriage in women with complications in early pregnancy. It aims to improve early pregnancy loss diagnosis and support for women. Healthcare professionals, commissioners, and women with complications in early pregnancy are the target audience. Recommendations include providing support and information with dignity and respect, early pregnancy assessment services available 7 days a week, and recognizing the symptoms and signs of ectopic pregnancy for prompt referral.\n\nIn women of reproductive age, consider offering a pregnancy test even with non-specific symptoms. Healthcare professionals should have access to pregnancy tests. Refer women with positive pregnancy tests and specific symptoms for further assessment. Exclude the possibility of ectopic pregnancy even without known risk factors. Refer women with early pregnancy complications for assessment based on clinical situation. Use ultrasound scans to diagnose viable intrauterine and tubal ectopic pregnancies. Consider signs indicating tubal ectopic pregnancy during ultrasound scans. Use serum hCG measurements cautiously in women with pregnancies of unknown location. Provide written information to women with pregnancies of unknown location for monitoring symptoms and accessing emergency care.\n\n1.4.29 For a woman with an increase in serum hCG levels greater than 63% after Ectopic pregnancy and miscarriage: diagnosis and initial management:\n- Inform her that she is likely to have a developing intrauterine pregnancy.\n- Offer her a transvaginal ultrasound scan to determine the location of the pregnancy between 7 and 14 days later. Consider an earlier scan for women with a serum hCG level greater than or equal to 1,500 IU/litre.\n- If a viable intrauterine pregnancy is confirmed, offer her routine antenatal care. \n- If a viable intrauterine pregnancy is not confirmed, refer her for immediate clinical review by a senior gynaecologist.\n\n1.4.30 For a woman with a decrease in serum hCG levels greater than 50% after 48 hours:\n- Inform her that the pregnancy is unlikely to continue but this is not confirmed.\n- Provide her with oral and written information about where she can access support and counselling services.\n- Ask her to take a urine pregnancy test 14 days after the second serum hCG test.\n\n1.4.31 For a woman with a decrease in serum hCG levels less than 50%, or an increase less than 63%, refer her for clinical review in the early pregnancy assessment service within 24 hours.\n\n1.4.32 For women with a pregnancy of unknown location, when using serial serum hCG measurements, do not use serum progesterone measurements as an adjunct to diagnose either viable intrauterine pregnancy or ectopic pregnancy.\n\nOffer systemic methotrexate to women with an unruptured tubal ectopic pregnancy who have no significant pain, an adnexal mass smaller than 35mm, a serum hCG level less than 1,500 IU/litre, and no visible heartbeat. Surgery should be offered if methotrexate is not acceptable or if the woman has significant pain, a larger adnexal mass, a visible heartbeat, or a serum hCG level of 5,000 IU/litre or more. Women with an ectopic pregnancy and a serum hCG level between 1,500 and 5,000 IU/litre can choose between methotrexate and surgical management if they meet certain criteria. Laparoscopic surgery should be performed when surgical treatment is needed, and competent surgeons should be available. Salpingectomy should be offered unless there are other risk factors for infertility, and salpingotomy can be considered for women with infertility risk factors. Anti-D immunoglobulin prophylaxis should be offered to all Rh-negative women undergoing surgery for an ectopic pregnancy or miscarriage. Do not offer it to women receiving solely medical management or with certain pregnancy conditions.\n\nOver the past 2 decades, there have been significant changes in the management of ectopic pregnancy and miscarriage, with a shift towards outpatient or day case care and the introduction of medical and expectant management as alternatives to surgery. However, there is a lack of research into the effects of these different approaches from the woman's perspective, particularly their psychological and emotional impact. Miscarriage is distressing for most women, and the type of management itself might affect women's need for counseling, resulting in a cost to the NHS. Therefore, further research in this area is important.\n\nA comparative study should be conducted to assess how the type of intervention impacts women's experience, including psychological and emotional outcomes. Currently, there is no evidence exploring the psychological impact of different treatments for ectopic pregnancy. A qualitative comparative study is needed to reduce the emotional impact of the condition and maximize women's emotional recovery in the short and long term.\n\nAdditionally, recommendations have been made regarding the use of ultrasound for diagnosing tubal ectopic pregnancy and the use of progestogens for preventing miscarriage. Standardizing practices across the NHS based on evidence will improve the diagnosis of ectopic pregnancy and reduce risks to women. The use of progestogens to prevent miscarriage is cost-effective and will standardize the preparation of progesterone used in such cases.\n\nFurthermore, recommendations have been made for the medical management of miscarriage, including the use of a combination of medications to reduce the need for surgical intervention. These recommendations aim to improve the management of miscarriage and reduce costs for the NHS.\n\nLastly, recommendations have been made for the expectant management of tubal ectopic pregnancy, offering clinically stable women an alternative to medical management. These recommendations aim to standardize the management of ectopic pregnancy and make expectant management available when clinically appropriate, potentially resulting in cost savings through a reduction in drug use.\n\nEctopic pregnancy and miscarriage have an adverse effect on the quality of life of many women. Approximately 20% of pregnancies miscarry, and miscarriages can cause considerable distress. Early pregnancy loss accounts for over 50,000 admissions in the UK annually. The rate of ectopic pregnancy is 11 per 1,000 pregnancies, with a maternal mortality of 0.2 per 1,000 estimated ectopic pregnancies. About two-thirds of these deaths are associated with substandard care. Women who do not access medical help readily are particularly vulnerable. Improvement in the diagnosis and management of early pregnancy loss is therefore of vital importance, in order to reduce the incidence of the associated psychological morbidity and avoid the unnecessary deaths of women with ectopic pregnancies.",
  "system_prompt": "You are a medical guidelines compliance checker. Your task is to analyze if the given clinical note follows the specified guideline and suggest improvements.",
  "guideline_id": "nice-guidance-2023-ectopic-pdf",
  "guideline_title": "NICE Guidance - 2023 - Ectopic.pdf"
}

A: ### Very Important Recommendations  
1. **Additional information needed** - Document serum hCG levels (current and trends if available) to guide management decisions.  
   **Reason:** The guideline (1.4.29â1.4.31) emphasizes the importance of serial hCG measurements in diagnosing and managing pregnancies of unknown location or non-viable pregnancies. The current note lacks hCG values, which are critical for confirming the diagnosis and guiding follow-up.  

2. **Different management plan** - Offer methotrexate as an alternative if the patient meets criteria (no significant pain, adnexal mass <35mm, hCG <1,500 IU/L, no heartbeat).  
   **Reason:** The guideline recommends methotrexate for unruptured ectopic pregnancies or non-viable intrauterine pregnancies meeting specific criteria (1.4.32). While the note assumes inevitable miscarriage, ectopic pregnancy must be definitively excluded, and methotrexate could be an option if criteria align.  

3. **Improved patient advice** - Provide written information on symptoms requiring urgent review (e.g., worsening pain, fever, heavy bleeding) and emergency contact details.  
   **Reason:** The guideline stresses written information for women with pregnancy complications (1.4.30) to ensure timely access to care and reduce risks associated with delayed presentation.  

### Somewhat Important Recommendations  
1. **Additional information needed** - Clarify if a senior gynaecologist reviewed the case pre-operatively, as recommended for uncertain diagnoses (e.g., no fetal pole on scan).  
   **Reason:** The guideline (1.4.31) advises senior review for pregnancies with inconclusive ultrasound findings or ambiguous hCG trends.  

2. **Improved patient advice** - Discuss psychological support options in more detail (e.g., specific counseling services, peer support groups).  
   **Reason:** The guideline highlights the emotional impact of miscarriage and recommends proactive support (see "Psychological and emotional impact" section).  

### Less Important Recommendations  
1. **Additional information needed** - Document whether serum progesterone was measured (though the guideline advises against its use).  
   **Reason:** The guideline explicitly discourages progesterone for diagnosing pregnancy location (1.4.32), but noting its absence aligns with best practices.  

2. **Improved patient advice** - Include statistics on success rates of surgical vs. medical management to aid decision-making.  
   **Reason:** While not explicitly required, the guidelineâs emphasis on informed choice (e.g., methotrexate vs. surgery) supports transparent risk/benefit discussions.  

### Unimportant Recommendations  
1. **Additional information needed** - Record the exact time of the last menstrual period (LMP) to the day, rather than "12 weeks ago."  
   **Reason:** The current documentation suffices for clinical decision-making, and the ultrasound findings override LMP discrepancies.  

---  
**Key Omissions in the Note:**  
- No mention of ectopic pregnancy exclusion despite guideline emphasis on this as a critical differential.  
- Lack of hCG trends to confirm non-viability (though ultrasound findings are likely sufficient here).  
- Anti-D prophylaxis is correctly planned, but the rationale (Rhesus-negative status) could be stated more explicitly.  

**Overall Alignment:** The note largely follows the guideline but could better address ectopic pregnancy exclusion, hCG monitoring, and patient information. The surgical plan is appropriate given retained products and patient preference, but alternatives (e.g., methotrexate) should be ruled out or offered if applicable.

--- Token Usage Report ---
Prompt tokens: 2115
Completion tokens: 729
Total tokens: 2844
Estimated cost: $0.001422